
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 National Eye Institute, NIH, Bethesda, MD; and
2 Yang Ming University, Taipei, Taiwan
Requests for reprints: Peggy S. Zelenka, NIH/NEI, Room 214, Building 6, 6 Center Drive MSC 2730, Bethesda, MD 20892-2730. E-mail: zelenkap{at}intra.nei.nih.gov
CDK5 and its activator, p35, are expressed in mouse corneal epithelium and can be coimmunoprecipited from corneal epithelial cell lysates. Immunostaining shows CDK5 and p35 in all layers of the corneal epithelium, especially along the basal side of the basal cells. Stable transfection of corneal epithelial cells with CDK5, which increases CDK5 kinase activity by approximately 33%, also increases the number of cells adhering to fibronectin and the strength of adhesion. CDK5 kinase activity seems to be required for this effect, because the kinase inactive mutation, CDK5-T33, either reduces adhesion or has no significant effect, depending on the level of expression. Using an in vitro scrape wound in confluent cultures of stably transfected cells to examine the effect of CDK5 on cell migration, we show that reoccupation of the wound area is significantly decreased by CDK5 and increased by CDK5-T33. These findings indicate that CDK5 may be an important regulator of adhesion and migration of corneal epithelial cells.
Key Words: CDK5 p35 adhesion cytoskeleton migration
This article has been cited by other articles:
![]() |
L. Liu, B. Schwartz, Y. Tsubota, E. Raines, H. Kiyokawa, K. Yonekawa, J. M. Harlan, and L. M. Schnapp Cyclin-Dependent Kinase Inhibitors Block Leukocyte Adhesion and Migration J. Immunol., February 1, 2008; 180(3): 1808 - 1817. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. DePinto, X.-J. Chu, X. Yin, M. Smith, K. Packman, P. Goelzer, A. Lovey, Y. Chen, H. Qian, R. Hamid, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer Ther., November 1, 2006; 5(11): 2644 - 2658. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Strock, J.-I. Park, E. K. Nakakura, G. S. Bova, J. T. Isaacs, D. W. Ball, and B. D. Nelkin Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res., August 1, 2006; 66(15): 7509 - 7515. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Ledee, C. Y. Gao, R. Seth, R. N. Fariss, B. K. Tripathi, and P. S. Zelenka A Specific Interaction between Muskelin and the Cyclin-dependent Kinase 5 Activator p39 Promotes Peripheral Localization of Muskelin J. Biol. Chem., June 3, 2005; 280(22): 21376 - 21383. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Lee, S. Voronov, K. Letinic, A. C. Nairn, G. Di Paolo, and P. De Camilli Regulation of the interaction between PIPKI{gamma} and talin by proline-directed protein kinases J. Cell Biol., February 28, 2005; 168(5): 789 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Y. Gao, M. A. Stepp, R. Fariss, and P. Zelenka Cdk5 regulates activation and localization of Src during corneal epithelial wound closure J. Cell Sci., August 15, 2004; 117(18): 4089 - 4098. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Hammond, L.-H. Tsai, and S.-S. Tan Control of Cortical Neuron Migration and Layering: Cell and Non Cell-Autonomous Effects of p35 J. Neurosci., January 14, 2004; 24(2): 576 - 587. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |